Vidan Diagnostics Announces Distribution Agreement with Medline Industries, Inc.
SAN ANTONIO, TX – August 24, 2018– Today, Vidan Diagnostics, LLC, announces that it has signed a distribution agreement with Medline Industries, Inc., the nation’s largest privately-held manufacturer and distributor of medical supplies providing products, education and services across the continuum of care.
The agreement follows US Food and Drug Administration 510(k) clearance and CLIA waiver for the Lucidplus™ β-Ketone Plus Glucose Monitoring System earlier this year. The Lucidplus™ is a whole blood, beta-hydroxybutyrate and glucose monitoring system intended for use by healthcare professionals at the point of care or in the central laboratory.
“As a start-up, it is critical to the success of our company that we partner with a leading and established distributor like Medline,” said Gilbert Mejia, CEO of Vidan Diagnostics. “Medline’s ability to reach Acute Care and Non-Acute Care laboratories in the U.S. will provide our potential customers access to novel products like our Lucidplus™.”
Further Acceptance of Beta-hydroxybutyrate
The availability of the Lucidplus™ and the diminished usage of urine-based (nitroprusside) ketone tests will further spur the acceptance of beta-hydroxybutyrate testing as the preferred method for monitoring patients with diabetic ketoacidosis, (DKA). Diabetic ketoacidosis is a complication of diabetes that occurs when ketones build up in the bloodstream.
Founded in 2015, Vidan Diagnostics LLC is a supplier of medical diagnostic products. It is focused on medical devices and reagents used for diagnosing and monitoring patients with conditions of diabetes, sepsis, anemia, heart disease and stroke. Vidan Diagnostics is dedicated to delivering proven and innovative products to all people in all places, in all aspects and stages of life with integrity and reliability. The company is headquartered in San Antonio, Texas.